Regeneron v. Aborder Products: Gate Patent Suit Stayed Pending Claims Construction
Regeneron Pharmaceuticals filed suit against Aborder Products Inc in the Northern District of Texas, asserting three gate-technology patents. After nine months, Judge Ada Brown administratively closed the case under a stay while claims construction briefing — due November 18, 2025 — and a preliminary injunction motion remain unresolved.
Three Gate Patents, One Stay: Inside Regeneron v. Aborder Products
On December 30, 2024, Regeneron Pharmaceuticals, Inc. filed a patent infringement action in the Northern District of Texas (Case No. 3:24-cv-03270) against Aborder Products Inc, asserting infringement of three patents — US11746589B1, US7975431B2, and US11085233B1 — all directed to gate product technology. Regeneron alleged that Aborder reaps both tangible and intangible benefits from sales of infringing gate products.
Rather than proceed to a merits determination, Judge Ada Brown administratively closed the case on September 30, 2025 — 274 days after filing — by entering a stay pending resolution of a preliminary injunction motion (ECF No. 13) and the completion of claims construction briefing. The court expressly noted this is not a final order, and directed the Clerk to stay but not terminate pending motions.
The administrative closure is consistent with courts managing docket efficiency where a dispositive motion — here, claims construction — will materially shape the litigation’s scope. The November 18, 2025 claims construction briefing deadline suggests the case could reopen in late 2025 or early 2026. The public record does not reveal any settlement discussions or licensing negotiations between the parties.
Filing to Case Stayed in 274 days
274 days to administrative closure — typical district court time-to-trial is 2–3 years
Administrative stay: what the court’s order means for both parties
Administrative closure is procedural, not a final disposition
An administrative closure under a stay suspends all proceedings without terminating the case. Judge Brown’s order explicitly states this is not a final order and reserves the right to reopen for oral argument. The Clerk is directed to stay — not terminate — pending motions, meaning the preliminary injunction (ECF No. 13) remains live. The case resumes automatically once claims construction briefing is resolved.
Non-final procedural orderRegeneron retains all claims; injunction relief still possible
For Regeneron, the stay preserves the preliminary injunction motion — a potentially powerful tool if granted, as it could halt Aborder’s gate product sales before any final judgment. Claims construction will be pivotal: a broad claim reading would strengthen Regeneron’s infringement theory across all three asserted patents. The stay does not prejudice Regeneron’s ability to seek full relief upon resumption.
Injunction motion preservedAborder faces renewed risk once briefing concludes in late 2025
Aborder Products gains temporary relief from active litigation pressure during the stay, but the underlying infringement claims and preliminary injunction threat remain unresolved. If the court construes the gate-product claims broadly, Aborder may face injunctive relief cutting off product sales. The administrative closure does not extinguish any liability exposure and Aborder must complete claims construction briefing by November 18, 2025.
Injunction risk remains liveGate product market faces continued uncertainty pending construction ruling
With three patents covering gate product technology at issue and a preliminary injunction motion pending, competitors and distributors in the gate products space should monitor the November 2025 claims construction briefing closely. A broad claim construction in Regeneron’s favour could reshape enforceability across the sector. The stay period may also provide a window for settlement or licensing discussions, though the public record is silent on this.
Monitor November 2025 briefingFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Regeneron Pharmaceuticals, Inc. | Company | Biopharmaceutical company — holder of US11746589B1, US7975431B2, and US11085233B1Search in Eureka ↗ |
| Defendant | Aborder Products Inc | Company | Aborder Products Inc — manufacturer and seller of gate products alleged to infringe asserted patentsSearch in Eureka ↗ |
| Plaintiff counsel | Bradley D Liddle | Attorney | Counsel for Regeneron Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Frederick A Tecce | Attorney | Counsel for Regeneron Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Michael Clayton Pomeroy | Attorney | Counsel for Regeneron Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | William David Carson | Attorney | Counsel for Regeneron Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Altima Advisors/Attorneys LLC | Law Firm | Representing Regeneron Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Cozen O’connor PC | Law Firm | Representing Regeneron Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Freeman Mathis & Gary LLP | Law Firm | Representing Regeneron Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Brian Casper | Attorney | Counsel for Aborder Products IncSearch in Eureka ↗ |
| Defendant counsel | Darin M. Klemchuk | Attorney | Counsel for Aborder Products IncSearch in Eureka ↗ |
| Defendant counsel | Mandi M Phillips | Attorney | Counsel for Aborder Products IncSearch in Eureka ↗ |
| Defendant counsel | Richard L. Wynne , Jr. | Attorney | Counsel for Aborder Products IncSearch in Eureka ↗ |
| Defendant counsel | Zachary Tiritilli | Attorney | Counsel for Aborder Products IncSearch in Eureka ↗ |
| Defendant law firm | Klemchuk PLLC | Law Firm | Representing Aborder Products IncSearch in Eureka ↗ |
| Presiding judge | Judge Ada Brown | Judge | Texas Northern District CourtSearch in Eureka ↗ |
Official order — verbatim text
The court’s order is expressly non-final and procedural in nature. Judge Brown’s decision to administratively close the case reflects docket management practice rather than any merits adjudication. By deferring the preliminary injunction ruling until after claims construction, the court follows the standard principle that injunction analysis depends on a defined claim scope. No infringement, validity, or damages findings have been made. Both parties retain their full positions pending the November 18, 2025 briefing deadline.
US11746589B1, US7975431B2 & US11085233B1 — Gate Product Technology Patents
The three asserted patents — US11746589B1, US7975431B2, and US11085233B1 — cover gate product technology across a span of application dates reflecting iterative development. US7975431B2 (application no. US12/156373) represents the earliest filing in the portfolio, while US11746589B1 (application no. US17/467138) and US11085233B1 (application no. US16/569667) represent later continuation or improvement filings. Together, they suggest a layered patent strategy protecting structural, design, and operational aspects of gate products.
For a biopharmaceutical firm like Regeneron asserting gate product patents, the commercial context is notable and may reflect a diversified IP portfolio strategy or technology spin-off. The three-patent assertion against a dedicated gate product manufacturer like Aborder signals that Regeneron considers these patents commercially valuable enough to seek injunctive relief, not merely damages. Competitors operating in the gate products sector should treat this portfolio as an active enforcement risk requiring independent FTO analysis.
Should your gate product line be cleared against US11746589B1 and related patents?
Any company designing, manufacturing, importing, or distributing gate products — including automated gates, agricultural gates, security barriers, or structural gate assemblies — should assess freedom to operate against US11746589B1, US7975431B2, and US11085233B1. Regeneron’s willingness to pursue preliminary injunctive relief indicates active enforcement posture. A positive FTO determination now is far less costly than defending an infringement suit after claims construction broadens the asserted scope.
PatSnap Eureka’s FTO Search Agent enables R&D and product teams to map their gate product designs against the claim language of all three asserted patents simultaneously. Eureka identifies relevant prior art, flags claim overlap, and benchmarks your design against the portfolio before the November 2025 claims construction order redefines enforceable scope. Run your FTO now, while the claim boundaries are still being litigated.
Run a freedom-to-operate analysis on US11746589B1 to assess your product’s exposure
Run FTO in Eureka →Similar Gate Product Patent Infringement Cases in Texas Federal Courts
Explore related patent infringement actions involving gate product technology and preliminary injunction motions filed in Texas federal district courts.
What this case signals for the gate products IP landscape
A preliminary injunction motion combined with multi-patent assertion signals aggressive enforcement posture — even before claim construction is settled.
Preliminary injunction filing early signals high-stakes enforcement intent
Regeneron filed a preliminary injunction motion (ECF No. 13) at an early stage, before claims construction was complete. This suggests confidence in the merits — or a commercial need to halt Aborder’s sales quickly. IP teams monitoring this space should note that courts will not rule on such motions until claim scope is defined, creating a structured litigation sequence.
Three-patent assertion raises invalidity and non-infringement complexity
Asserting three distinct patents — US11746589B1, US7975431B2, and US11085233B1 — across gate product technology increases litigation complexity and defence costs for Aborder. For patent holders, multi-patent assertion can improve enforcement leverage. For potential defendants in adjacent product categories, each patent represents a separate FTO obligation.
Regeneron v Aborder — key questions answered
As of September 30, 2025, the case is administratively closed under a court-ordered stay. Judge Ada Brown stayed all proceedings pending completion of claims construction briefing, due November 18, 2025, and a ruling on Regeneron’s preliminary injunction motion (ECF No. 13). This is not a final order — the case can be reopened.
Regeneron asserted three patents: US11746589B1 (application no. US17/467138), US7975431B2 (application no. US12/156373), and US11085233B1 (application no. US16/569667). All three relate to gate product technology. The products at issue are described as Aborder’s infringing gate products.
An administrative closure is a procedural case management tool. It suspends activity on the docket without dismissing the case or ruling on the merits. All pending motions — including the preliminary injunction — are stayed but not terminated. The court retains jurisdiction and can reopen the case once the triggering conditions (claims construction ruling) are met.
Regeneron’s preliminary injunction motion (ECF No. 13) seeks to halt Aborder’s sales of allegedly infringing gate products before final judgment. Courts typically require the movant to show likelihood of success on the merits, irreparable harm, balance of hardships, and public interest. Judge Brown deferred ruling until after claims construction, consistent with standard practice in patent cases.
The court ordered claims construction briefing to be completed by November 18, 2025. Once the court rules on the pending motions following that briefing, the stay will lift and proceedings will resume. The exact reopening timeline depends on judicial scheduling, but late 2025 or early 2026 is a reasonable expectation based on the briefing deadline set by Judge Brown.
PatSnap Eureka searches patents and litigation data to answer instantly.